[Asia Economy Reporter Hyunseok Yoo] Neurophat, a specialized company in artificial intelligence (AI) solutions for brain diseases, announced on the 23rd that it has obtained certification from the Ministry of Food and Drug Safety (MFDS) for its brain electrical stimulation treatment planning software, ‘Neurophat TMS LAB (NEUROPHET TMS LAB).’
Brain imaging treatment planning software is a newly established medical device certification category by the MFDS this year. It is software that analyzes brain images to enable treatment simulation. So far, the only products that have received this certification are ‘Neurophat tES LAB (NEUROPHET tES LAB)’ and ‘Neurophat TMS LAB.’
The representative non-surgical methods of brain electrical stimulation treatment are transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The ‘Neurophat tES LAB,’ which received certification earlier this month, is tDCS treatment planning software, and the newly certified ‘Neurophat TMS LAB’ is TMS treatment planning software.
Transcranial magnetic stimulation (TMS) is a brain stimulation technique that activates or inhibits nerve cells in specific areas by passing a magnetic field generated by an electromagnetic coil through the head surface and skull. It is a non-invasive procedure that can achieve effects easily without anesthesia and is being therapeutically applied to various brain neurological disorders.
‘Neurophat TMS LAB’ analyzes brain magnetic resonance imaging (MRI) and reconstructs it into a three-dimensional model, allowing various TMS simulations on the modeled brain images. Through this, it calculates the optimal parameters considering the individual’s brain structure to design brain stimulation treatment.
Kim Donghyun, Chief Technology Officer (CTO) of Neurophat, said, "It is a meaningful achievement that Neurophat has received both the first and second certifications for brain imaging treatment planning software from the MFDS," adding, "In the future, we will develop various treatment planning software beyond direct current stimulation and magnetic stimulation to become a leading company in the brain disease AI solution field."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
